• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    MindMed Appoints Gregg Chief Regulatory & Quality Assurance Officer

    BUSINESSWIRE

    MindMed to Participate in Upcoming Investor Conferences

    BUSINESSWIRE

    MindMed Reports Q3 2024 Financial Results & Business Updates

    BUSINESSWIRE

    MindMed To Host Q3 2024 Results Call And Business Update

    BUSINESSWIRE

    MindMed Announces New Employee Inducement Grants

    BUSINESSWIRE

    MindMed to Participate in September Investor Conferences

    BUSINESSWIRE

    MindMed Reports Second Quarter 2024 Financial Results and Business Updates

    BUSINESSWIRE

    Mind Medicine (MindMed) Inc. Announces Proposed Public Offering

    BUSINESSWIRE

    Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering

    BUSINESSWIRE

    MindMed To Host Q2 2024 Financial Results And Business Update Call

    BUSINESSWIRE

    MindMed to Present at Canaccord Genuity’s 44th Annual Growth Conference

    BUSINESSWIRE

    MindMed Appoints Stephanie Fagan as Chief Corporate Affairs Officer

    BUSINESSWIRE

    MindMed Patents MM120 Orally Disintegrating Tablet

    BUSINESSWIRE

    MindMed to be Included in Russell 2000® and Russell 3000® Indexes

    BUSINESSWIRE

    MindMed to Present at H.C. Wainwright Neuro Perspectives Virtual Conference

    BUSINESSWIRE

    MindMed Has Productive End-Of-Phase 2 Meeting With FDA For MM120 In GAD

    BUSINESSWIRE

    Optimi Secures Import Permit For MDMA, Psilocybin From Mind Medicine

    GLOBENEWSWIRE

    MindMed to Participate in June Conferences

    BUSINESSWIRE

    MindMed to Participate at May Investor Conferences

    BUSINESSWIRE

    MindMed Reports First Quarter 2024 Financial Results and Business Updates

    BUSINESSWIRE

    Progress Toward a New GAD Treatment Paradigm

    FIERCE BIOTECH

    MindMed To Host Q1 2024 Results Call, Webcast, Business Update

    BUSINESSWIRE

    MindMed to Present at Upcoming May Medical Conferences

    BUSINESSWIRE

    MindMed to Present at Upcoming April Medical Conferences

    BUSINESSWIRE

    MindMed Announces Voluntary Delisting from Cboe Canada

    BUSINESSWIRE

    MindMed to Participate in the Leerink Partners 2024 Global Biopharma Conference

    BUSINESSWIRE

    MindMed Receives FDA Breakthrough Therapy Designation From Phase 2B of MM120

    BUSINESSWIRE

    MindMed Announces Pricing of Underwritten Offering of Common Shares

    BUSINESSWIRE

    MindMed to Host Conference Call and Webcast to Discuss Data Update for MM120

    BUSINESSWIRE

    MindMed Reports 2023 Financial Results and Business Updates

    BUSINESSWIRE

    MindMed to Host Conference Call and Webcast to Discuss 2023 Financial Results

    BUSINESSWIRE

    MindMed to Participate in the 34th Annual Oppenheimer Conference

    BUSINESSWIRE

    MindMed Announces Business Update and Anticipated Milestones for 2024

    BUSINESSWIRE

    MindMed links LSD to reduced anxiety in phase 2b, plots phase 3

    FIERCE BIOTECH

    MindMed to Host Conference to Discuss Third Quarter 2023 Financial Results

    BUSINESSWIRE

    MindMed Completes Enrollment of Phase 2a Trial of MM-120

    BUSINESSWIRE

    MindMed to Present Data on the Preclinical Activity of MM-402

    BUSINESSWIRE

    MindMed to Participate in the TD Cowen 3rd Annual Neuropsychiatry Summit

    BUSINESSWIRE

    MindMed Completes Enrollment of Phase 2b Trial of MM-120

    BUSINESSWIRE

    MindMed Announces Agreement With Catalent for Its Patented Zydis

    BUSINESSWIRE

    MindMed Reports Second Quarter 2023 Financial Results and Business Highlights

    BUSINESSWIRE

    MindMed to Host Conference Discuss Q2 2023 Financial Results

    BUSINESSWIRE

    MindMed to Participate in the H.C. Wainwright 4th Annual Neuropsychiatry VC

    BUSINESSWIRE

    MindMed Announces Election of All Six Company Nominees at Annual Meeting

    BUSINESSWIRE

    MindMed Provides Overview of Clinical Progress & Corporate Updates

    BUSINESSWIRE

    MindMed to Host Investor Day June 2023

    BUSINESSWIRE

    MindMed to Participate at Upcoming Investor Conferences

    BUSINESSWIRE

    MindMed Releases Investor Presentation Highlighting How the Company is Unlocking the Power of Psychedelics for Patients and Shareholders

    BUSINESSWIRE

    MindMed Publishes Report Validating MindMed’s MM-120 Drug Development Strategy

    BUSINESSWIRE

    MindMed to Present Data on the Preclinical Activity of MM-402

    BUSINESSWIRE

    MindMed completes 50% subject enrolment and dosing in GAD therapy trial

    CLINICAL TRIALS ARENA

    MindMed Announces Enrollment Milestone in Phase 2b Trial of MM-120

    BUSINESSWIRE

    MindMed Reports First Quarter 2023 Financial Results and Business Highlights

    BUSINESSWIRE

    MindMed to Host Conference Call and Webcast to Discuss First Quarter 2023

    BUSINESSWIRE

    MindMed to Participate in May Investor Conferences

    BUSINESSWIRE

    MindMed Collaborators Announce Data from Phase 2 Trial of LSD in MDD

    BUSINESSWIRE

    MindMed Appoints Mark R. Sullivan as Chief Legal Officer and Corporate Secretary

    BUSINESSWIRE

    MindMed Reports Full Year 2022 Financial Results and Business Highlights

    BUSINESSWIRE

    MindMed to Participate in March Investor Conferences

    BUSINESSWIRE

    MindMed Provides Corporate Update and 2023 Outlook

    PR NEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.